Skip to main content
Smart Investors Daily
LF

NASDAQ · LFCR

Lifecore Biomedical, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$6.39

Up+$0.02 (+0.31%)

Updated Nov 21, 2026, 8:25 PM

SID Score

4.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
292.19M
P/E ratio
-7.47
Dividend yield
0.00%
52-week range
$3.63 – $8.98
Volume
218.74K
Avg. volume
177.01K

Price performance · LFCR

LFCR price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 20, 2026

LFCR closed at $6.39 after 21 trading sessions, down 0.16% for the selected period.

Last close
$6.39
Period change
-0.16%
Period low
$6.36
Period high
$6.52
Daily close
View OHLC price history
LFCR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 20, 2026$6.37$6.39$6.369$6.39218.74K
Nov 19, 2026$6.39$6.40$6.345$6.37319.06K
Nov 18, 2026$6.40$6.41$6.39$6.40147.54K
Nov 17, 2026$6.41$6.42$6.39$6.39192.77K
Nov 16, 2026$6.41$6.42$6.40$6.41565.92K
Nov 13, 2026$6.40$6.42$6.38$6.4294K
Nov 12, 2026$6.38$6.40$6.38$6.40109.89K
Nov 11, 2026$6.37$6.40$6.37$6.40149.72K
Nov 10, 2026$6.37$6.385$6.37$6.37369.58K
Nov 9, 2026$6.38$6.39$6.36$6.37142.91K
Nov 6, 2026$6.38$6.39$6.36$6.36780.49K
Nov 5, 2026$6.45$6.45$6.375$6.40700.06K
Nov 4, 2026$6.44$6.45$6.41$6.44270.83K
Nov 3, 2026$6.41$6.44$6.405$6.42297.92K
Nov 2, 2026$6.40$6.42$6.375$6.39800.23K
Oct 30, 2026$6.48$6.4992$6.315$6.401.02M
Oct 29, 2026$6.52$6.52$6.47$6.52240.91K
Oct 28, 2026$6.44$6.51$6.43$6.51365.16K
Oct 27, 2026$6.36$6.44$6.36$6.44441.61K
Oct 26, 2026$6.41$6.44$6.40$6.44436.37K
Oct 23, 2026$6.36$6.40$6.36$6.40224.04K

Latest LFCR news

The latest Smart Investors Daily articles mentioning LFCR.

LFCR research

Overview

Company profile and research snapshot.

Company profile

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$6.50
Implied upside
—
Analysts
11
LFCR recent ratings
DateFirmRatingTarget
Sep 29, 2026Barrington ResearchMarket Perform—
Sep 28, 2026William BlairMarket Perform—
Jun 16, 2026Barrington ResearchOutperform—
Apr 29, 2026Barrington ResearchOutperform—
Mar 27, 2026Barrington ResearchOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 4, 2026

Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update

-- Multiple New Business Wins Continue to Strengthen Growing Pipeline -- CHASKA, Minn., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced results for the third quarter and nine months ended September 30, 2026. CEO Commentary “During the third quarter, Lifecore secured two new technology transfer projects. One will support process performance qualific

Yahoo · Oct 23, 2026

Is Lifecore Biomedical (LFCR) an Asymmetric Risk-Reward in Pharma Contract Manufacturing?

Diranko Capital, an independent investment management firm, released its Q3 2026 investor letter. The letter can be downloaded here. In the quarter, Diranko Capital achieved a 2.2% after-fee return, matching the MSCI ACWI and outperforming the MSCI World Small Cap (-2.9%). Since inception, the firm has delivered a 14.7% annualized after-fee return, exceeding both benchmark […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.